Biotricity Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Biotricity prevailing Real Value cannot be determined due to lack of data. The current price of Biotricity is $0.0. Our model approximates the value of Biotricity from analyzing the firm fundamentals such as Return On Equity of -41.01, current valuation of 38.87 M, and Profit Margin of (1.17) % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Biotricity's price fluctuation is out of control at this time. Calculation of the real value of Biotricity is based on 3 months time horizon. Increasing Biotricity's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biotricity is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biotricity Stock. However, Biotricity's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0 | Real 0.0 | Hype 0.0 |
The intrinsic value of Biotricity's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biotricity's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biotricity helps investors to forecast how Biotricity stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biotricity more accurately as focusing exclusively on Biotricity's fundamentals will not take into account other important factors: Biotricity Total Value Analysis
Biotricity is currently forecasted to have valuation of 38.87 M with market capitalization of 10.02 M, debt of 23.88 M, and cash on hands of 2.89 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biotricity fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
38.87 M | 10.02 M | 23.88 M | 2.89 M |
Biotricity Investor Information
About 49.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.66. Biotricity had not issued any dividends in recent years. The entity had 1:6 split on the 3rd of July 2023. Based on the key measurements obtained from Biotricity's financial statements, Biotricity is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Biotricity Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biotricity has an asset utilization ratio of 203.0 percent. This suggests that the Company is making $2.03 for each dollar of assets. An increasing asset utilization means that Biotricity is more efficient with each dollar of assets it utilizes for everyday operations.Biotricity Ownership Allocation
Biotricity holds a total of 21.48 Million outstanding shares. Biotricity retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Biotricity Profitability Analysis
The company reported the previous year's revenue of 12.06 M. Net Loss for the year was (14.09 M) with profit before overhead, payroll, taxes, and interest of 4.57 M.About Biotricity Valuation
Our relative valuation model uses a comparative analysis of Biotricity. We calculate exposure to Biotricity's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biotricity's related companies.Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. Biotricity operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.
Biotricity Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 9.5 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Biotricity Stock
If you are still planning to invest in Biotricity check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biotricity's history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |